InvestSMART

Pro Medicus Limited (ASX:PME)

ALERT: Price-sensitive ASX Announcement for PME
Current share price for PME : $159.820 -138.38 (-46.41%)+
Announcement
Release
8 Oct 2025 9:19AM
Price at Release
$298.200
Full Release
download
Summary
Pro Medicus Limited, through its European subsidiary Visage Imaging, GmbH, has signed a 5-year, A$10 million Enterprise PACS contract with University Hospital Heidelberg (UKHD) and the German Cancer Research Institute (DKFZ), including associated hospitals. This deal involves replacing and consolidating three legacy PACS systems and expanding Visage's presence in the German and European markets. The contract highlights the need for advanced technology in supporting diagnostics, innovative treatments, and translational research at these leading academic medical and research centers. Visage 7, the imaging platform provided by Pro Medicus, will offer a scalable solution for seamless data access and improve clinical and research workflows. The partnership aims to enhance diagnostic tools for clinicians and support researchers in handling large-scale imaging data efficiently.
Key Points
  • Pro Medicus signed a 5-year, A$10 million contract.
  • Deal with University Hospital Heidelberg and DKFZ.
  • Involves replacing and consolidating three legacy PACS.
  • Expands Visage's footprint in Germany and Europe.
  • Visage 7 platform supports advanced diagnostics and research.
  • Deal enhances Pro Medicus's position in the healthcare imaging market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.